Business
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AMLSAN DIEGO and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that it has entered into an amended and restated arrangement agreement dated February 23, 2026 (the “Amended and Restated Arrangement Agreement”) amending and restating the arrangement agreement dated
About this update from Hanmi Pharmaceutical Co., Ltd.
[{"type":"image","alt":"Aptose Biosciences, Inc.","displaySize":"","headline":null,"caption":"Aptose Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/b498b08d7b00ed826b23627f4658fc2d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W_19l.RGaQd7rMmL1joc4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b498b08d7b00ed826b23627f4658fc2d","width":300,"height":112}},"lazy":false},{"type":"text","content":"Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AML","length":151,"tagName":"p"},{"type":"text","content":"SAN DIEGO and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that it has entered into an amended and restated arrangement agreement dated February 23, 2026 (the “Amended and Restated Arrangement Agreement”) amending and restating the arrangement agreement dated November 18, 2025 (the “Original Arrangement Agreement”), pursuant to which Aptose will continue from the Canada Business Corporations Act to the Business Corporations Act (Alberta) (“ABCA”) (the “Continuance”) and subsequently be acquired by HS North America Ltd. (the “Purchaser”), a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd. (“Hanmi” and together with the Purchaser, the “Hanmi Purchasers”), by way of a statutory plan of arrangement under the ABCA (the “Arrangement” and, together with the Continuance, the “Transaction”).","length":890,"tagName":"p"},{"type":"text","content":"The Amended and Restated Arrangement Agreement amends and restates the Original Arrangement Agreement to, among other things, schedule a new date for the special meeting of shareholders to seek approval of the Transaction (the “Meeting”), originally scheduled to be held on January 16, 2026 (the “Original Meeting”) which has been reconvened to March 31, 2026 at 11:00 a.m. (EST) (the “Reconvened Meeting”). The Original Meeting was postponed to address comments raised by the United States Securities and Exchange Commission (“SEC”) on the Company’s transaction statement on Schedule 13E-3, as amended.","length":603,"tagName":"p"},{"type":"text","content":"Aptose has prepare...